中国医学科学院学报

高级检索
中国医学科学院学报

中国医学科学院学报 ›› 2021, Vol. 43 ›› Issue (3): 475-480.doi: 10.3881/j.issn.1000-503X.12666

• 综述 • 上一篇    下一篇

肿瘤浸润淋巴细胞在三阴性乳腺癌免疫治疗中的应用进展

赵佳琳1,王学晶2,曹希2,孙强2()   

  1. 1中国医学科学院 北京协和医学院 北京协和医院 超声医学科,北京 100730
    2中国医学科学院 北京协和医学院 北京协和医院 乳腺外科,北京 100730
  • 收稿日期:2020-02-29 出版日期:2021-06-30 发布日期:2021-07-09
  • 通讯作者: 孙强 E-mail:sunqiangpumc@sina.com
  • 基金资助:
    北京协和医学院中央高校基本科研业务费专项资金(3332020001)

Progress of Tumor Infiltrating Lymphocytes in Immunotherapy of Triple Negative Breast Cancer

ZHAO Jialin1,WANG Xuejing2,CAO Xi2,SUN Qiang2()   

  1. 1Department of Ultrasound,PUMC Hospital,CAMS and PUMC,Beijing 100730,China
    2Department of Breast Surgery,PUMC Hospital,CAMS and PUMC,Beijing 100730,China
  • Received:2020-02-29 Published:2021-06-30 Online:2021-07-09
  • Contact: SUN Qiang E-mail:sunqiangpumc@sina.com
  • Supported by:
    Fundamental Research Funds for the Central Universities,PUMC(3332020001)

摘要:

乳腺癌已成为中国女性发病率最高的癌症,而三阴性乳腺癌(TNBC)因缺乏有效的治疗靶点,与其他类型乳腺癌相比预后较差。肿瘤浸润淋巴细胞(TILs)是存在于肿瘤周围的一群异质性淋巴细胞,大量研究认为,TILs是宿主免疫系统对肿瘤抗原存在免疫反应的标志。目前已有文献报道TILs对于乳腺癌预后的预测作用,其研究热点主要集中在TNBC上,本文总结了TILs在TNBC免疫治疗中的应用进展。

关键词: 三阴性乳腺癌, 肿瘤浸润淋巴细胞, 免疫治疗, 预后

Abstract:

Breast cancer has become the most common cancer for women in China.Lack of effective therapeutic targets,triple negative breast cancer(TNBC)has poorer prognosis compared with other subtypes of breast cancer.Tumor infiltrating lymphocytes(TILs)are a group of heterogeneous lymphocytes around the tumor,which are believed as immunoreactive products of host immune response to tumor antigens.At present,there have been reports on the predictive effect of TILs on the prognosis of breast cancer,and the available studies focus mainly on TNBC.This article briefly reviews the recent progress of tumor infiltrating lymphocytes in immunotherapy of TNBC.

Key words: triple negative breast cancer, tumor infiltrating lymphocytes, immunotherapy, prognosis

中图分类号: